PLEASANTON, Calif., April 18, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bristol Myers Squibb, Eli Lilly and Company, Genentech, Janssen, and Merck will be keynote speakers at the 2023 Veeva Commercial Summit on May 2-3 in Boston. Speakers from leading and emerging biopharmas will share how advancements in digital engagement, content, data, and analytics elevate commercial strategy and execution.
One of the largest industry events in North America for commercial and medical affairs professionals, Veeva Commercial Summit will host nearly 1,500 people across more than 90 sessions. Veeva CEO Peter Gassner will headline the opening keynote with a bold vision to connect sales, medical, and marketing for commercial excellence. Veeva experts will join the stage to showcase the company's plans for future software, data, and services innovations to help companies get the right treatments to patients more efficiently.
Other featured keynotes include:
"The industry is transforming engagement with healthcare professionals by creating greater synergies across sales, medical, and marketing," said Paul Shawah, executive vice president at Veeva. "We look forward to bringing the industry together to share effective strategies and insights that advance commercial excellence."
The event is open to life sciences industry professionals. Register and see the full agenda and program details at veeva.com/Summit.
Additional Information
To register for Veeva Commercial Summit, visit: veeva.com/Summit/Register Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com
Contact:
Alison Borris
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$217.02 |
Daily Change: | 7.02 3.34 |
Daily Volume: | 773,766 |
Market Cap: | US$35.140B |
September 05, 2024 September 05, 2024 August 28, 2024 August 22, 2024 August 13, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB